{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:19:40Z","timestamp":1767993580192,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12944-015-0032-3","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T11:34:00Z","timestamp":1428924840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Bing","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfa","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuimei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,14]]},"reference":[{"issue":"129","key":"32_CR1","first-page":"S49","volume":"2014","author":"DC Goff Jr","year":"2013","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R: ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 2014 (129): S49-73.","journal-title":"Circulation"},{"issue":"63","key":"32_CR2","first-page":"2889","volume":"2014","author":"NJ Stone","year":"2013","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey MCN, Blum CB, Eckel RH: ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 2014 (63): 2889-934.","journal-title":"J Am Coll Cardiol"},{"key":"32_CR3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.mayocp.2014.06.016","volume":"89","author":"F Lopez-Jimenez","year":"2014","unstructured":"Lopez-Jimenez F, Simha V, Thomas RJ, Allison TG, Basu A, Fernandes R: A summary and critical assessment of the 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. Mayo Clin Proc. 2014, 89: 1257-78. 10.1016\/j.mayocp.2014.06.016","journal-title":"Mayo Clin Proc"},{"issue":"64","key":"32_CR4","first-page":"601","volume":"2014","author":"SC Smith Jr","year":"2013","unstructured":"Smith SC, Grundy SM: ACC\/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol. 2013, 2014 (64): 601-12.","journal-title":"J Am Coll Cardiol"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011, 32: 1345-61. 10.1093\/eurheartj\/ehr112","journal-title":"Eur Heart J"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA: Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014, 371: 22-31. 10.1056\/NEJMoa1307095","journal-title":"N Engl J Med"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A: Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014, 371: 32-41. 10.1056\/NEJMoa1308027","journal-title":"N Engl J Med"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.arteri.2014.09.004","volume":"26","author":"NJ Millan","year":"2014","unstructured":"Millan NJ, Pedro-Botet MJ, Pinto SX: Atherogenic dyslipidemia and residual risk. State of the art in 2014. Clin Investig Arterioscler. 2014, 26: 287-92. 10.1016\/j.arteri.2014.09.004. 10.1016\/j.arteri.2014.09.004","journal-title":"Clin Investig Arterioscler"},{"key":"32_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(03)00156-4","volume":"171","author":"MJ Chapman","year":"2003","unstructured":"Chapman MJ: Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 2003, 171: 1-13. 10.1016\/S0021-9150(03)00156-4","journal-title":"Atherosclerosis"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1517\/14656566.2014.972365","volume":"15","author":"AS Wierzbicki","year":"2014","unstructured":"Wierzbicki AS, Viljoen A: Fibrates and niacin: is there a place for them in clinical practice. Expert Opin Pharmacother. 2014, 15: 2673-80. 10.1517\/14656566.2014.972365","journal-title":"Expert Opin Pharmacother"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-014-0159-y","volume":"13","author":"A Tenenbaum","year":"2014","unstructured":"Tenenbaum A, Klempfner R, Fisman EZ: Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014, 13: 159- 10.1186\/s12933-014-0159-y","journal-title":"Cardiovasc Diabetol"},{"key":"32_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0021-9150(00)00634-1","volume":"155","author":"D Milosavljevic","year":"2001","unstructured":"Milosavljevic D, Griglio S, Le NG, Chapman MJ: Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis. 2001, 155: 251-60. 10.1016\/S0021-9150(00)00634-1","journal-title":"Atherosclerosis"},{"key":"32_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2014.11.002","volume-title":"Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis","author":"HD Choi","year":"2014","unstructured":"Choi HD, Shin WG, Lee JY, Kang BC. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.LID - S1537-1891(14)00172-4 [pii]LID - doi:10.1016\/j.vph.2014.11.002. Vascul Pharmacol. 2014."},{"issue":"Suppl A","key":"32_CR14","first-page":"A24","volume":"19","author":"MJ Chapman","year":"1998","unstructured":"Chapman MJ, Guerin M, Bruckert E: Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998, 19 (Suppl A): A24-30.","journal-title":"Eur Heart J"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M: The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014, 2: 655-66. 10.1016\/S2213-8587(13)70191-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"32_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362: 1563-74. 10.1056\/NEJMoa1001282","journal-title":"N Engl J Med"},{"key":"32_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1517\/14656560903575639","volume":"11","author":"SM Schima","year":"2010","unstructured":"Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM: Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother. 2010, 11: 731-8. 10.1517\/14656560903575639","journal-title":"Expert Opin Pharmacother"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2337\/dc05-2465","volume":"29","author":"J Shepherd","year":"2006","unstructured":"Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006, 29: 1220-6. 10.2337\/dc05-2465","journal-title":"Diabetes Care"},{"key":"32_CR19","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","volume":"376","author":"J Armitage","year":"2010","unstructured":"Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010, 376: 1658-69. 10.1016\/S0140-6736(10)60310-8","journal-title":"Lancet"},{"key":"32_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1155\/2013\/563717","volume":"35","author":"A Cai","year":"2013","unstructured":"Cai A, Li L, Zhang Y, Mo Y, Mai W, Zhou Y: Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013, 35: 551-9. 10.1155\/2013\/563717","journal-title":"Dis Markers"},{"key":"32_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1155\/2013\/432136","volume":"34","author":"A Cai","year":"2013","unstructured":"Cai A, Zheng D, Qiu R, Mai W, Zhou Y: Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013, 34: 323-31. 10.1155\/2013\/432136","journal-title":"Dis Markers"},{"key":"32_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/clc.21988","volume":"35","author":"I Kardys","year":"2012","unstructured":"Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J: Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol. 2012, 35: 482-9. 10.1002\/clc.21988","journal-title":"Clin Cardiol"},{"key":"32_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2011.04.031","volume":"218","author":"A Massot","year":"2011","unstructured":"Massot A, Pelegri D, Penalba A, Arenillas J, Boada C, Giralt D: Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis. 2011, 218: 181-7. 10.1016\/j.atherosclerosis.2011.04.031","journal-title":"Atherosclerosis"},{"key":"32_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-511X-13-41","volume":"13","author":"D Zheng","year":"2014","unstructured":"Zheng D, Zeng F, Cai A, Liao H, Liu L, Qiu R: Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis. 2014, 13: 41- 10.1186\/1476-511X-13-41","journal-title":"Lipids Health Dis"},{"key":"32_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/hrt.2010.204990","volume":"97","author":"GF Watts","year":"2011","unstructured":"Watts GF, Karpe F: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011, 97: 350-6. 10.1136\/hrt.2010.204990","journal-title":"Heart"},{"key":"32_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","volume":"217","author":"M Lee","year":"2011","unstructured":"Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011, 217: 492-8. 10.1016\/j.atherosclerosis.2011.04.020","journal-title":"Atherosclerosis"},{"key":"32_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1023\/A:1024207925670","volume":"17","author":"A Gaw","year":"2003","unstructured":"Gaw A: HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc Drugs Ther. 2003, 17: 53-62. 10.1023\/A:1024207925670","journal-title":"Cardiovasc Drugs Ther"},{"key":"32_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jff.2013.12.006","volume":"6","author":"P Scicchitano","year":"2014","unstructured":"Scicchitano P, Cameli M, Maiello M, Amedeo MP, Lorenza MM, Salvatore N: Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014, 6: 11-32. 10.1016\/j.jff.2013.12.006. 10.1016\/j.jff.2013.12.006","journal-title":"J Funct Foods"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-015-0032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-015-0032-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-015-0032-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-015-0032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:48:33Z","timestamp":1630579713000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-015-0032-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1186\/s12944-015-0032-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,14]]},"assertion":[{"value":"21 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}